CAR immune cells: design principles, resistance and the next generation
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …
malignant cells but also an altered immune response. The inhibition and reprogramming of …
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
[HTML][HTML] Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …
Scalable manufacturing of CAR T cells for cancer immunotherapy
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T
cell therapies for hematologic malignancies. With the current transition of CAR T cell …
cell therapies for hematologic malignancies. With the current transition of CAR T cell …
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells
Chimeric antigen receptor (CAR) T-cell toxicities resembling hemophagocytic
lymphohistiocytosis (HLH) occur in a subset of patients with cytokine release syndrome …
lymphohistiocytosis (HLH) occur in a subset of patients with cytokine release syndrome …
Enhancing pediatric access to cell and gene therapies
Increasing numbers of cell and gene therapies (CGTs) are emerging to treat and cure
pediatric diseases. However, small market sizes limit the potential return on investment …
pediatric diseases. However, small market sizes limit the potential return on investment …
[HTML][HTML] Recent advances and challenges in cancer immunotherapy
C Peterson, N Denlinger, Y Yang - Cancers, 2022 - mdpi.com
Simple Summary Immunotherapy helps a person's immune system to target tumor cells.
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …
Born to survive: how cancer cells resist CAR T cell therapy
Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …